14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CING vs PRLD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Cingulate Inc. (CING) is the stronger overall head-to-head candidate over Prelude Therapeutics Incorporated (PRLD) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas PRLD carries 47.5/100 (HOLD) at $3.30 (N/M Forward P/E, -294.8% operating margin).
Composite vs. Pillar Nuance: While PRLD currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. CING 44.8/100 HOLD), CING captures the overall institutional head-to-head verdict (2–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -294.8% operating margin) and revenue trajectory (+0.0% vs. +41.0% YoY).
Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.9); meanwhile PRLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs PRLD. Trailing 12-month operating profitability (CING 0.0% vs PRLD -294.8%) and valuation multiples (CING N/M vs PRLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $275.3M market capitalization and -294.8% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CING vs PRLD Key Questions & Quantitative Answers
As of Nov 17, 2026, Cingulate Inc. (CING) is the stronger overall head-to-head candidate over Prelude Therapeutics Incorporated (PRLD) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas PRLD carries 47.5/100 (HOLD) at $3.30 (N/M Forward P/E, -294.8% operating margin). Composite vs. Pillar Nuance: While PRLD currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. CING 44.8/100 HOLD), CING captures the overall institutional head-to-head verdict (2–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -294.8% operating margin) and revenue trajectory (+0.0% vs. +41.0% YoY). Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.9); meanwhile PRLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PRLD leads the Growth & Scale pillar: CING posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PRLD at +41.0% YoY revenue growth and +0.0% YoY earnings growth on $22M TTM revenue (100.0% gross margin, -294.8% operating margin). On trailing 12-month operating scale, CING generates N/A in USD-normalized revenue versus $22M for PRLD. In operating R&D and SG&A reinvestment, CING deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PRLD.
PRLD screens cheaper on headline valuation multiples. CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PRLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CING (-198.7% ROE) versus PRLD (-57.7% ROE) capital efficiency.
In options market volatility and institutional positioning, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk). By comparison, PRLD carries 137.6% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 6.57x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 73% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.